Ethos Biosciences

Ethos Biosciences designs, develops, and manufactures diagnostics that are accurate, repeatable, and easy to use. Ethos Biosciences was formed as a subsidiary of Ott Scientific in 2018 to drive healthcare innovation by providing diagnostic tools for scientists and practitioners. In November 2018, Ethos Biosciences acquired the Exocell diagnostic operation in Philadelphia from Glycadia Pharmaceuticals. Exocell was founded in 1988 by Dr. Margo Cohen, MD/PhD to explore diagnostic and therapeutic solutions for diabetes. Exocell quickly became a leader in nephrology diagnostics with 15 patents and over 2000 research citations. The Exocell brand continues to service the top research, academic, and industrial...

Nephrology,assay development,elisa,biomarkers,antibodies,proteins,oxidative stress,stains,reagents,lateral flow,contract development and manufacturing,contract manufacturing,histology,hematology,veterinary pathology,cdmo,diagnostics,metabolic disorders,acr,and ckd assays

Ethos biosciences operates in the Biotechnology research industry.

Ethos biosciences's revenue is 11m - 100m

Ethos biosciences has 11 - 50 employees.